Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer

Molecular Oncology

Volumn 5, Issue 6, 2011, Pages 545-554

  Liu, Chen ^a   Sun, Bin ^a   An, Ni ^a   Tan, Weifeng ^a   Cao, Lu ^a   Luo, Xiangji ^a   Yu, Yong ^a   Feng, Feiling ^a   Li, Bin ^a   Wu, Mengchao ^a   Su, Changqing ^a   Jiang, Xiaoqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gallbladder cancer; Gene therapy; Oncolytic adenovirus; Tumor specific promoter

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; ONCOLYTIC ADENOVIRUS; PROTEIN P53; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; GALLBLADDER CANCER; LIVER CANCER; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 81855176011     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.10.001     Document Type: Article

References (49)

1. Bagheri N., Shiina M., Lauffenburger D.A., Korn W.M. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by mek-inhibition. PLoS Comput. Biol. 2011, 7:e1001085.
2. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., Nieva J., Hwang T.H., Moon A., Patt R., Pelusio A., Le Boeuf F., Burns J., Evgin L., De Silva N., Cvancic S., Robertson T., Je J.E., Lee Y.S., Parato K., Diallo J.S., Fenster A., Daneshmand M., Bell J.C., Kirn D.H. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
3. Budanov A.V., Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
4. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrère F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougnères P., Von Kalle C., Fischer A., Cavazzana-Calvo M., Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
5. Castillo J.P., Kowalik T.F. Human cytomegalovirus immediate early proteins and cell growth control. Gene 2002, 290:19-34.
6. Chen L., Chen D., Manome Y., Dong Y., Fine H.A., Kufe D.W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 1995, 96:2775-2782.
7. Christine C.W., Starr P.A., Larson P.S., Eberling J.L., Jagust W.J., Hawkins R.A., VanBrocklin H.F., Wright J.F., Bankiewicz K.S., Aminoff M.J. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73:1662-1669.
8. Cideciyan A.V., Hauswirth W.W., Aleman T.S., Kaushal S., Schwartz S.B., Boye S.L., Windsor E.A., Conlon T.J., Sumaroka A., Roman A.J., Byrne B.J., Jacobson S.G. Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med. 2009, 361:725-727.
9. Duffy M.J., O'donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:49-60.
10. Feldser D.M., Kostova K.K., Winslow M.M., Taylor S.E., Cashman C., Whittaker C.A., Sanchez-Rivera F.J., Resnick R., Bronson R., Hemann M.T., Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468:572-575.
11. Garcia-Saez I., Lacroix F.B., Blot D., Gabel F., Skoufias D.A. Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein survivin and the oncogenic viral protein HBx.J. Mol. Biol. 2011, 405:331-340.
12. Hallenbeck P.L., Chang Y.N., Hay C., Golightly D., Stewart D., Lin J., Phipps S., Chiang Y.L. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 1999, 10:1721-1733.
13. He X.P., Su C.Q., Wang X.H., Pan X., Tu Z.X., Gong Y.F., Gao J., Liao Z., Jin J., Wu H.Y., Man X.H., Li Z.S. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 2009, 285:89-98.
14. Hemminki O., Bauerschmitz G., Hemmi S., Lavilla-Alonso S., Diaconu I., Guse K., Koski A., Desmond R.A., Lappalainen M., Kanerva A., Cerullo V., Pesonen S., Hemminki A. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 2011, 18:288-296.
15. Hew H.C., Liu H., Miki Y., Yoshida K. PKCδ regulates Mdm2 independently of p53 in the apoptotic response to DNA damage. Mol. Carcinog. 2011, 10.1002/mc.20748.
16. Huang P.I., Chang J.F., Kirn D.H., Liu T.C. Targeted genetic and viral therapy for advanced head and neck cancers. Drug Discov. Today 2009, 14:570-578.
17. Gene therapy clinical trials worldwide. J. Gene Med. 2011, updated June 2011, (accessed 22.09.11). http://www.wiley.com//legacy/wileychi/genmed/clinical.
18. Johnson L., Shen A., Boyle L., Kunich J., Pandey K., Lemmon M., Hermiston T., Giedlin M., McCormick F., Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002, 1:325-337.
19. Khalil A., Morgan R.N., Adams B.R., Golding S.E., Dever S.M., Rosenberg E., Povirk L.F., Valerie K. ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 2011, 10:481-491.
20. Krambeck A.E., Dong H., Thompson R.H., Kuntz S.M., Lohse C.M., Leibovich B.C., Blute M.L., Sebo T.J., Cheville J.C., Parker A.S., Kwon E.D. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:1749-1756.
21. Kurihara T., Brough D.E., Kovesdi I., Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 2000, 106:763-771.
22. Lane D.P., Cheok C.F., Lain S. p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2010, 2:a001222.
23. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
24. Lu W., Zheng S., Li X.F., Huang J.J., Zheng X., Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol. 2004, 10:3634-3638.
25. Lu P., Yang X., Huang Y., Lu Z., Miao Z., Liang Q., Zhu Y., Fan Q. Antitumor activity of a combination of rAd2p53 adenoviral gene therapy and radiotherapy in esophageal carcinoma. Cell Biochem. Biophys. 2011, 59:147-152.
26. Ma J., He X., Wang W., Huang Y., Chen L., Cong W., Gu J., Hu H., Shi J., Li L., Su C. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig. Dis. Sci. 2009, 54:1425-1431.
27. Maguire A.M., High K.A., Auricchio A., Wright J.F., Pierce E.A., Testa F., Mingozzi F., Bennicelli J.L., Ying G.S., Rossi S., Fulton A., Marshall K.A., Banfi S., Chung D.C., Morgan J.I., Hauck B., Zelenaia O., Zhu X., Raffini L., Coppieters F., De Baere E., Shindler K.S., Volpe N.J., Surace E.M., Acerra C., Lyubarsky A., Redmond T.M., Stone E., Sun J., McDonnell J.W., Leroy B.P., Simonelli F., Bennett J. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374:1597-1605.
28. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
29. Ohashi M., Kanai F., Tateishi K., Taniguchi H., Marignani P.A., Yoshida Y., Shiratori Y., Hamada H., Omata M. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem. Biophys. Res. Commun. 2001, 282:529-535.
30. Opyrchal M., Aderca I., Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol. Biol. 2009, 542:705-717.
31. Osaki T., Tanio Y., Tachibana I., Hosoe S., Kumagai T., Kawase I., Oikawa S., Kishimoto T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994, 54:5258-5261.
32. Parr M.J., Manome Y., Tanaka T., Wen P., Kufe D.W., Kaelin W.G., Fine H.A. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 1997, 3:1145-1149.
33. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 2005, 16:1016-1027.
34. Peng X.Y., Won J.H., Rutherford T., Fujii T., Zelterman D., Pizzorno G., Sapi E., Leavitt J., Kacinski B., Crystal R., Schwartz P., Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 2001, 61:4405-4413.
35. Rödel F., Reichert S., Sprenger T., Gaipl U.S., Mirsch J., Liersch T., Fulda S., Rödel C. The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr. Med. Chem. 2011, 18:191-199.
36. Rao Y.K., Wu A.T., Geethangili M., Huang M.T., Chao W.J., Wu C.H., Deng W.P., Yeh C.T., Tzeng Y.M. Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem. Res. Toxicol. 2011, 24:238-245.
37. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997, 57:2559-2563.
38. Rubanyi G.M. The future of human gene therapy. Mol. Aspects Med. 2001, 22:113-142.
39. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
40. Shariat S.F., Ashfaq R., Karakiewicz P.I., Saeedi O., Sagalowsky A.I., Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109:1106-1113.
41. Song X., Zhou Y., Jia R., Xu X., Wang H., Hu J., Ge S., Fan X. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest. Ophthalmol. Vis. Sci. 2010, 51:2626-2635.
42. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., Liu C., Cui Z., Xue H., Wu H., Yang Q., Zhang B., Liu X., Wu M., Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 2006, 13:918-927.
43. Su C., Cao H., Tan S., Huang Y., Jia X., Jiang L., Wang K., Chen Y., Long J., Liu X., Wu M., Wu X., Qian Q. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol. Sci. 2008, 106:242-250.
44. Tsukuda K., Wiewrodt R., Molnar-Kimber K., Jovanovic V.P., Amin K.M. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 2002, 62:3438-3447.
45. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
46. Wang X., Su C., Cao H., Li K., Chen J., Jiang L., Zhang Q., Wu X., Jia X., Liu Y., Wang W., Liu X., Wu M., Qian Q. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 2008, 7:1598-1603.
47. Yang Z.X., Wang D., Wang G., Zhang Q.H., Liu J.M., Peng P., Liu X.H. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2010, 136:625-630.
48. Zhang Q., Nie M., Sham J., Su C., Xue H., Chua D., Wang W., Cui Z., Liu Y., Liu C., Jiang M., Fang G., Liu X., Wu M., Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res. 2004, 64:5390-5397.
49. Zhang Q., Chen G., Peng L., Wang X., Yang Y., Liu C., Shi W., Su C., Wu H., Liu X., Wu M., Qian Q. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 2006, 12:6523-6531.